Earnings Releases·Oct 27, 2026, 7:08 AM ET

IQVIA — Third Quarter 2026 Earnings Summary

Q3 2026 revenue reached $4,428 million (up 8.0% YoY), while adjusted diluted EPS rose 11.3% to $3.34; year-to-date adjusted diluted EPS increased 10.4% to $9.38.
Full-year 2026 guidance was raised across all metrics: revenue to $17,350–$17,500 million, adjusted EBITDA to $4,025–$4,055 million, and adjusted diluted EPS to $12.90–$13.00.
R&D Solutions backlog stands at $32.6 billion with $9.4 billion expected to convert to revenue in the next twelve months, supported by net new bookings of $11.7 billion (up 14% YoY).
Capital allocation included $950 million in common stock repurchases year-to-date, while the company maintains a net leverage ratio of 3.45x and free cash flow of $667 million for the quarter.
A $2.1 billion backlog adjustment for inactive trials was confirmed to have no impact on historical results, 2026 guidance, or revenue estimates.